Reappraisal of GIP Pharmacology for Metabolic Diseases

Trends in Molecular Medicine

Volumn 22, Issue 5, 2016, Pages 359-376

  Finan, Brian ^a,b,c   Müller, Timo D ^a,b,c   Clemmensen, Christoffer ^a,b,c   Perez Tilve, Diego ^d   DiMarchi, Richard D ^e   Tschöp, Matthias H ^a,b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^e INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GASTRIC INHIBITORY POLYPEPTIDE RECEPTOR; GLUCOSE BLOOD LEVEL; HORMONE RECEPTOR; INSULIN;

GENETIC VARIATION; GLUCOSE BLOOD LEVEL; HUMAN; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; RODENT MODEL; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, TYPE 2; METABOLIC DISEASES; METABOLISM; MOUSE; PHYSIOLOGY;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; METABOLIC DISEASES; MICE; OBESITY; RECEPTORS, GASTROINTESTINAL HORMONE;

EID: 84962046497     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2016.03.005     Document Type: Review

References (135)

1. Moore B. On the treatment of diabetes mellitus by acid extract of duodenal mucous membrane. Biochem. J. 1906, 1:28-38.
2. Bayliss W.M., Starling E.H. The mechanism of pancreatic secretion. J. Physiol. 1902, 28:325-353.
3. Banting F.G., et al. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 1922, 12:141-146.
4. McIntyre N., et al. New interpretation of oral glucose tolerance. Lancet 1964, 2:20-21.
5. Elrick H., et al. Plasma insulin response to oral and intravenous glucose administration. J. Clin. Endocrinol. Metab. 1964, 24:1076-1082.
6. Nauck M.A., et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J. Clin. Endocrinol. Metab. 1986, 63:492-498.
7. Holst J.J., et al. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011, 34(Suppl. 2):S251-S257.
8. Nauck M., et al. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986, 29:46-52.
9. Brown J.C., Pederson R.A. A multiparameter study on the action of preparations containing cholecystokinin-pancreozymin. Scand. J. Gastroenterol. 1970, 5:537-541.
10. Brown J.C. A gastric inhibitory polypeptide. I. The amino acid composition and the tryptic peptides. Can. J. Biochem. 1971, 49:255-261.
11. Dupre J., et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J. Clin. Endocrinol. Metab. 1973, 37:826-828.
12. Ebert R., et al. Preservation of incretin activity after removal of gastric inhibitory polypeptide (GIP) from rat gut extracts by immunoadsorption. Diabetologia 1983, 24:449-454.
13. Lauritsen K.B., et al. Gastric inhibitory polypeptide (GIP) and insulin release after small-bowel resection in man. Scand. J. Gastroenterol. 1980, 15:833-840.
14. Lund P.K., et al. Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:345-349.
15. Bell G.I., et al. Exon duplication and divergence in the human preproglucagon gene. Nature 1983, 304:368-371.
16. Miyawaki K., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002, 8:738-742.
17. Tseng C.C., et al. Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat. J. Clin. Invest. 1996, 98:2440-2445.
18. McClean P.L., et al. GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1746-E1755.
19. Sparre-Ulrich A.H., et al. Species-specific action of (Pro3)GIP - an efficacious agonist on human GIP receptor, but partial agonist and competitive antagonist on rat and mouse GIP receptors. Br. J. Pharmacol. 2016, 173:27-38.
20. Hojberg P.V., et al. Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia 2009, 52:199-207.
21. Nyberg J., et al. Immunohistochemical distribution of glucose-dependent insulinotropic polypeptide in the adult rat brain. J. Neurosci. Res. 2007, 85:2099-2119.
22. Fujita Y., et al. Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion. Gastroenterology 2010, 138:1966-1975.
23. Ugleholdt R., et al. Prohormone convertase 1/3 is essential for processing of the glucose-dependent insulinotropic polypeptide precursor. J. Biol. Chem. 2006, 281:11050-11057.
24. Fujita Y., et al. Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298:G608-G614.
25. (1-42) in high-fat fed mice. J. Endocrinol. 2011, 208:265-271.
26. Timper K., et al. Glucose-dependent insulinotropic peptide stimulates glucagon-like peptide 1 production by pancreatic islets via interleukin-6, produced by alpha cells. Gastroenterology 2016, Published online March 10, 2016. 10.1053/j.gastro.2016.03.003.
27. Meier J.J., et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003, 46:798-801.
28. Chia C.W., et al. Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes. Diabetes 2009, 58:1342-1349.
29. Christensen M., et al. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 2011, 60:3103-3109.
30. Christensen M., et al. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. Diabetes 2015, 64:72-78.
31. McIntosh C.H., et al. Glucose-dependent insulinotropic polypeptide signaling in pancreatic beta-cells and adipocytes. J. Diabetes Investig. 2012, 3:96-106.
32. Campbell J.E., et al. TCF1 links GIPR signaling to the control of beta cell function and survival. Nat. Med. 2016, 22:84-90.
33. Shu L., et al. Decreased TCF7L2 protein levels in type 2 diabetes mellitus correlate with downregulation of GIP- and GLP-1 receptors and impaired beta-cell function. Hum. Mol. Genet. 2009, 18:2388-2399.
34. Ehses J.A., et al. Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway. J. Biol. Chem. 2002, 277:37088-37097.
35. Miki T., et al. Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility. Diabetes 2005, 54:1056-1063.
36. Kim S.J., et al. A novel mechanism for the suppression of a voltage-gated potassium channel by glucose-dependent insulinotropic polypeptide: protein kinase A-dependent endocytosis. J. Biol. Chem. 2005, 280:28692-28700.
37. Miyawaki K., et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:14843-14847.
38. Hansotia T., et al. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J. Clin. Invest. 2007, 117:143-152.
39. Smith E.P., et al. The role of beta cell glucagon-like peptide-1 signaling in glucose regulation and response to diabetes drugs. Cell Metab. 2014, 19:1050-1057.
40. Mohammad S., et al. A naturally occurring GIP receptor variant undergoes enhanced agonist-induced desensitization, which impairs GIP control of adipose insulin sensitivity. Mol. Cell. Biol. 2014, 34:3618-3629.
41. Roed S.N., et al. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking. J. Biol. Chem. 2015, 290:1233-1243.
42. Schelshorn D., et al. Lateral allosterism in the glucagon receptor family: glucagon-like peptide 1 induces G-protein-coupled receptor heteromer formation. Mol. Pharmacol. 2012, 81:309-318.
43. Nauck M.A., et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 1993, 91:301-307.
44. Vilsboll T., et al. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide - regardless of etiology and phenotype. J. Clin. Endocrinol. Metab. 2003, 88:4897-4903.
45. Gault V.A., et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J. Endocrinol. 2002, 175:525-533.
46. Holst J.J., et al. The pathogenesis of NIDDM involves a defective expression of the GIP receptor. Diabetologia 1997, 40:984-986.
47. Hinke S.A., et al. Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (βTC-3) cells to glucose-dependent insulinotropic polypeptide. J. Endocrinol. 2000, 165:281-291.
48. Saxena R., et al. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat. Genet. 2010, 42:142-148.
49. Salera M., et al. Gastric inhibitory polypeptide release after oral glucose: relationship to glucose intolerance, diabetes mellitus, and obesity. J. Clin. Endocrinol. Metab. 1982, 55:329-336.
50. Calanna S., et al. Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. Diabetes Care 2013, 36:3346-3352.
51. Lynn F.C., et al. Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes 2001, 50:1004-1011.
52. Xu G., et al. Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 2007, 56:1551-1558.
53. Muller T.D., et al. Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J. Pept. Sci. 2012, 18:383-393.
54. Finan B., et al. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci. Transl. Med. 2013, 5:209ra151.
55. Gupta D., et al. Physiologic and pharmacologic modulation of glucose-dependent insulinotropic polypeptide (GIP) receptor expression in beta-cells by peroxisome proliferator-activated receptor (PPAR)-gamma signaling: possible mechanism for the GIP resistance in type 2 diabetes. Diabetes 2010, 59:1445-1450.
56. Speliotes E.K., et al. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat. Genet. 2010, 42:937-948.
57. Fortin J.P., et al. Pharmacological characterization of human incretin receptor missense variants. J. Pharmacol. Exp. Ther. 2010, 332:274-280.
58. Usdin T.B., et al. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993, 133:2861-2870.
59. Yip R.G., et al. Functional GIP receptors are present on adipocytes. Endocrinology 1998, 139:4004-4007.
60. Lardinois C.K., et al. The postprandial response of gastric inhibitory polypeptide to various dietary fats in man. J. Am. Coll. Nutr. 1988, 7:241-247.
61. Tseng C.C., et al. Regulation of glucose-dependent insulinotropic peptide gene expression by a glucose meal. Am. J. Physiol. 1994, 266:G887-G891.
62. Bailey C.J., et al. Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets. Acta Endocrinol. (Copenh.) 1986, 112:224-229.
63. Eckel R.H., et al. Gastric inhibitory polypeptide enhanced lipoprotein lipase activity in cultured preadipocytes. Diabetes 1979, 28:1141-1142.
64. Kim S.J., et al. Adipocyte expression of the glucose-dependent insulinotropic polypeptide receptor involves gene regulation by PPARgamma and histone acetylation. J. Lipid Res. 2011, 52:759-770.
65. Gogebakan O., et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11β-hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. Diabetes 2012, 61:292-300.
66. Oben J., et al. Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J. Endocrinol. 1991, 130:267-272.
67. Ebert R., et al. Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats. Horm. Metab. Res. 1991, 23:517-521.
68. Wasada T., et al. Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs. J. Clin. Invest. 1981, 68:1106-1107.
69. Beck B., Max J.P. Direct metabolic effects of gastric inhibitory polypeptide (GIP): dissociation at physiological levels of effects on insulin-stimulated fatty acid and glucose incorporation in rat adipose tissue. Diabetologia 1986, 29:68.
70. Ahlqvist E., et al. Link between GIP and osteopontin in adipose tissue and insulin resistance. Diabetes 2013, 62:2088-2094.
71. Kim S.J., et al. Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J. Biol. Chem. 2007, 282:34139-34147.
72. Ugleholdt R., et al. Transgenic rescue of adipocyte glucose-dependent insulinotropic polypeptide receptor expression restores high fat diet-induced body weight gain. J. Biol. Chem. 2011, 286:44632-44645.
73. -/- mice. Endocrinology 1998, 139:3127-3132.
74. Pi-Sunyer X., et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N. Engl. J. Med. 2015, 373:11-22.
75. -/- mice. Diabetes 1998, 47:1046-1052.
76. Pamir N., et al. Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. Am. J. Physiol. Endocrinol. Metab. 2003, 284:E931-E939.
77. Nasteska D., et al. Chronic reduction of GIP secretion alleviates obesity and insulin resistance under high-fat diet conditions. Diabetes 2014, 63:2332-2343.
78. Althage M.C., et al. Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet. J. Biol. Chem. 2008, 283:18365-18376.
79. Fulurija A., et al. Vaccination against GIP for the treatment of obesity. PLoS ONE 2008, 3:e3163.
80. Irwin N., et al. Active immunisation against gastric inhibitory polypeptide (GIP) improves blood glucose control in an animal model of obesity-diabetes. Biol. Chem. 2009, 390:75-80.
81. Boylan M.O., et al. Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice. Am. J. Physiol. Endocrinol. Metab. 2015, 309:E1008-E1018.
82. Nakamura T., et al. Biological and functional characteristics of a novel low-molecular weight antagonist of glucose-dependent insulinotropic polypeptide receptor, SKL-14959, in vitro and in vivo. Diabetes Obes. Metab. 2012, 14:511-517.
83. Ravn P., et al. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J. Biol. Chem. 2013, 288:19760-19772.
84. Deacon C.F., et al. GIP-(3-42) does not antagonize insulinotropic effects of GIP at physiological concentrations. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E468-E475.
85. Gelling R.W., et al. GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul. Pept. 1997, 69:151-154.
86. Gault V.A., et al. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 2002, 290:1420-1426.
87. Irwin N., et al. Effects of short-term chemical ablation of the GIP receptor on insulin secretion, islet morphology and glucose homeostasis in mice. Biol. Chem. 2004, 385:845-852.
88. Gault V.A., et al. Chemical ablation of gastric inhibitory polypeptide receptor action by daily (Pro3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities of islet structure in obesity-related diabetes. Diabetes 2005, 54:2436-2446.
89. Gault V.A., et al. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007, 50:1752-1762.
90. Irwin N., et al. Early administration of the glucose-dependent insulinotropic polypeptide receptor antagonist (Pro3)GIP prevents the development of diabetes and related metabolic abnormalities associated with genetically inherited obesity in ob/ob mice. Diabetologia 2007, 50:1532-1540.
91. Al-Sabah S., et al. Selectivity of peptide ligands for the human incretin receptors expressed in HEK-293 cells. Eur. J. Pharmacol. 2014, 741:311-315.
92. Faivre E., et al. Effects of acute and chronic administration of GIP analogues on cognition, synaptic plasticity and neurogenesis in mice. Eur. J. Pharmacol. 2012, 674:294-306.
93. Medeiros M.D., Turner A.J. Processing and metabolism of peptide-YY: pivotal roles of dipeptidylpeptidase-IV, aminopeptidase-P, and endopeptidase-24.11. Endocrinology 1994, 134:2088-2094.
94. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
95. Kim S.J., et al. GIP-overexpressing mice demonstrate reduced diet-induced obesity and steatosis, and improved glucose homeostasis. PLoS ONE 2012, 7:e40156.
96. Ambati S., et al. GIP-dependent expression of hypothalamic genes. Physiol. Res. 2011, 60:941-950.
97. Herbach N., et al. Overexpression of a dominant negative GIP receptor in transgenic mice results in disturbed postnatal pancreatic islet and beta-cell development. Regul. Pept. 2005, 125:103-117.
98. Renner S., et al. Glucose intolerance and reduced proliferation of pancreatic beta-cells in transgenic pigs with impaired glucose-dependent insulinotropic polypeptide function. Diabetes 2010, 59:1228-1238.
99. Ceperuelo-Mallafre V., et al. Disruption of GIP/GIPR axis in human adipose tissue is linked to obesity and insulin resistance. J. Clin. Endocrinol. Metab. 2014, 99:E908-E919.
100. Gault V.A., et al. Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide. J. Endocrinol. 2003, 176:133-141.
101. Irwin N., et al. Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide. J. Med. Chem. 2005, 48:1244-1250.
102. Irwin N., et al. A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes. J. Pharmacol. Exp. Ther. 2005, 314:1187-1194.
103. Irwin N., et al. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice. J. Pept. Sci. 2007, 13:400-405.
104. Kerr B.D., et al. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem. Pharmacol. 2009, 78:1008-1016.
105. Martin C.M., et al. A novel acylated form of (d-Ala2)GIP with improved antidiabetic potential, lacking effect on body fat stores. Biochim. Biophys. Acta 2013, 1830:3407-3413.
106. 2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity. Diabetes 1999, 48:758-765.
107. Gault V.A., et al. Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes. Biochem. J. 2002, 367:913-920.
108. O'Harte F.P., et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia 2002, 45:1281-1291.
109. 2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo. Metabolism 2003, 52:679-687.
110. Widenmaier S.B., et al. A GIP receptor agonist exhibits beta-cell anti-apoptotic actions in rat models of diabetes resulting in improved beta-cell function and glycemic control. PLoS ONE 2010, 5:e9590.
111. 2]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats. Diabetes 2002, 51:652-661.
112. Kuhn-Wache K., et al. Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance. Adv. Exp. Med. Biol. 2000, 477:187-195.
113. Finan B., et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat. Med. 2015, 21:27-36.
114. Lamont B.J., Drucker D.J. Differential antidiabetic efficacy of incretin agonists versus DPP-4 inhibition in high fat fed mice. Diabetes 2008, 57:190-198.
115. Varol C., et al. Long-acting glucose-dependent insulinotropic polypeptide ameliorates obesity-induced adipose tissue inflammation. J. Immunol. 2014, 193:4002-4009.
116. 2 fragment with potent pancreatic amylase inhibitory activity. Regul. Pept. 1992, 39:9-17.
117. Harada N., et al. A novel GIP receptor splice variant influences GIP sensitivity of pancreatic beta-cells in obese mice. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E61-E68.
118. Tatarkiewicz K., et al. A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents. Diabetes Obes. Metab. 2014, 16:75-85.
119. Gault V.A., et al. C-terminal mini-PEGylation of glucose-dependent insulinotropic polypeptide exhibits metabolic stability and improved glucose homeostasis in dietary-induced diabetes. Biochem. Pharmacol. 2008, 75:2325-2333.
120. Meier J.J., et al. Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects. Diabetes 2004, 53(Suppl. 3):S220-S224.
121. Irwin N., et al. Metabolic effects of sustained activation of the GLP-1 receptor alone and in combination with background GIP receptor antagonism in high fat-fed mice. Diabetes Obes. Metab. 2009, 11:603-610.
122. Nauck M.A., et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J. Clin. Endocrinol. Metab. 1993, 76:912-917.
123. Mentis N., et al. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 2011, 60:1270-1276.
124. Fosgerau K., Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov. Today 2015, 20:122-128.
125. Finan B., et al. Emerging opportunities for the treatment of metabolic diseases: glucagon-like peptide-1 based multi-agonists. Mol. Cell. Endocrinol. 2015, 418:42-54.
126. Day J.W., et al. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers 2012, 98:443-450.
127. Gelling R.W., et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:1438-1443.
128. Sadry S.A., Drucker D.J. Emerging combinatorial hormone therapies for the treatment of obesity and T2DM. Nat. Rev. Endocrinol. 2013, 9:425-433.
129. Kim J.Y., et al. Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J. Clin. Invest. 2007, 117:2621-2637.
130. Kusminski C.M., et al. MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity. Nat. Med. 2012, 18:1539-1549.
131. Ye J.M., et al. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia 2004, 47:1306-1313.
132. Li Y., et al. Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model. Neuropharmacology 2016, 101:255-263.
133. Cao L., et al. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain. Neuroreport 2016, 27:384-391.
134. Ding K.H., et al. Impact of glucose-dependent insulinotropic peptide on age-induced bone loss. J. Bone Miner. Res. 2008, 23:536-543.
135. Poerregaard P., et al. A novel GIP receptor agonist enhances the body weight lowering effect of liraglutide in diet-induced mice and has the potential for once-weekly administration in humans. Presented at the 51st EASD Annual Meeting 2015.